除了KROCUS联合研究,氟泽雷塞单药治疗KRAS G12C突变晚期NSCLC也有良好表现。 在2023年欧洲肿瘤内科学会亚洲大会(ESMO Asia)上,吴一龙教授汇报了氟泽雷塞针对我国NSCLC患者的一项临床II期注册研究。初步研究结果显示,氟泽雷塞治疗KRAS G12C突变...
The conference theme was “Promoting Equity and Enhancing Optimal Care Delivery.” The conference chairs were Shabbir Alibhai, MD, MSc, FRCPC, and Martine Puts, RN, PhD, FAAN,... Multiple Myeloma Genomics/Genetics Issues in Oncology The ASCO Post Staff / Thursday, February 20, 2025 11:08 ...
Dr.Silke Gillessen:Yes,and all your interesting questions that you just gave to me,we will discuss that very,very profoundly with all world experts at the APCCC 2024 in Lugano end of April.and everyone who wants to come can register now.So the registration is open,it’s not restricted.E...
Day One will host a conference call and webcast on June 4, 2023, at 6:00 p.m. CT. Participants can access the conference call live via webcast from theInvestors & Mediapage of Day One’s website. To pa...
Clinical Trial Registration Number NCT03548207 Citation J Clin Oncol 41, 2023 (suppl 16; abstr 8009) DOI 10.1200/JCO.2023.41.16_suppl.8009 Abstract # 8009 Poster Bd # 1 RECOMMENDED FOR YOU Toviewitems recommended for you, please sign in to your ASCO.org account.Sign Inchevron_right ...
The Phase 3 registrational trial will randomize patients with previously untreated, HLA-A*02:01-positive, advanced melanoma to IMC-F106C + nivolumab versus nivolumab or nivolumab + relatlimab, depending on the country where the patient is enrolled. The study will initially randomize to three arm...
在2023年欧洲肿瘤内科学会亚洲大会(ESMO Asia)上,吴一龙教授汇报了氟泽雷塞针对我国NSCLC患者的一项临床II期注册研究。初步研究结果显示,氟泽雷塞治疗KRAS G12C突变晚期NSCLC的确认ORR(cORR)为46.6%,DCR为90.5%,中位无进展生存期(mPFS)为8.3个月。 吴一龙教授表示,与此前获美国FDA批准的两款KRAS G12C抑制剂(Sotor...
2023年美国临床肿瘤学会年会(ASCO)将于2023年6月2日至6日在美国芝加哥举行,全球肿瘤学界最大的年度大会汇集了来自世界各地的肿瘤学专业人士,一年一度的ASCO年会汇聚了全球临床肿瘤学研究的精英,被公认为全球最重要的肿瘤学术会议。教育课程以世界知名的教师为特色,讨论最先进的治疗方式、新疗法和该领域正在进行的争议...
Under the terms of a clinical trial collaboration and supply agreement, Immunocore will sponsor and fund this registrational Phase 3 clinical trial, and Bristol Myers Squibb will provide nivolumab. Audio Webcast Immunocore will host a conference call today, May 31, 2024 at 7:15 PM ET / 6:15...